New obesity drug SA030 enters first human safety trial

NCT ID NCT07479862

Not yet recruiting Disease control Sponsor: Suzhou Siran Biotechnology Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage study tests a single dose of SA030 injection in 40 overweight or obese adults aged 18–55. The main goal is to check safety and how the body handles the drug. It is the first time SA030 is given to humans, so results will guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SA030 injection
What this could lead to: If safe and effective, this could point toward a new treatment for weight management.
What could go wrong: This is a very early Phase 1 trial with only 40 people, focused on safety. It may not lead to an approved treatment, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESE OVERWEIGHT

Contacts and locations

Locations

CMAX Clinical Research Pty Ltd North Terrace

Adelaide, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.